"Ovarian Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
| Descriptor ID |
D010051
|
| MeSH Number(s) |
C04.588.322.455 C13.351.500.056.630.705 C13.351.937.418.685 C19.344.410 C19.391.630.705
|
| Concept/Terms |
Ovarian Neoplasms- Ovarian Neoplasms
- Neoplasm, Ovarian
- Ovarian Neoplasm
- Ovary Neoplasms
- Neoplasm, Ovary
- Neoplasms, Ovary
- Ovary Neoplasm
- Neoplasms, Ovarian
Ovary Cancer- Ovary Cancer
- Cancer, Ovary
- Cancers, Ovary
- Ovary Cancers
- Ovarian Cancer
- Cancer, Ovarian
- Cancers, Ovarian
- Ovarian Cancers
- Cancer of Ovary
- Cancer of the Ovary
|
Below are MeSH descriptors whose meaning is more general than "Ovarian Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Ovarian Neoplasms".
This graph shows the total number of publications written about "Ovarian Neoplasms" by people in this website by year, and whether "Ovarian Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 5 | 0 | 5 |
| 1997 | 7 | 1 | 8 |
| 1998 | 2 | 1 | 3 |
| 1999 | 2 | 1 | 3 |
| 2000 | 6 | 4 | 10 |
| 2001 | 12 | 0 | 12 |
| 2002 | 2 | 2 | 4 |
| 2003 | 4 | 1 | 5 |
| 2004 | 4 | 2 | 6 |
| 2005 | 7 | 1 | 8 |
| 2006 | 7 | 1 | 8 |
| 2007 | 8 | 2 | 10 |
| 2008 | 12 | 5 | 17 |
| 2009 | 18 | 2 | 20 |
| 2010 | 13 | 3 | 16 |
| 2011 | 19 | 2 | 21 |
| 2012 | 23 | 5 | 28 |
| 2013 | 14 | 2 | 16 |
| 2014 | 26 | 4 | 30 |
| 2015 | 28 | 1 | 29 |
| 2016 | 24 | 4 | 28 |
| 2017 | 25 | 1 | 26 |
| 2018 | 23 | 4 | 27 |
| 2019 | 32 | 5 | 37 |
| 2020 | 14 | 1 | 15 |
| 2021 | 30 | 1 | 31 |
| 2022 | 26 | 1 | 27 |
| 2023 | 35 | 0 | 35 |
| 2024 | 19 | 3 | 22 |
| 2025 | 14 | 0 | 14 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ovarian Neoplasms" by people in Profiles.
-
Genomic Landscapes of Endometrioid and Mucinous Ovarian Cancers and Morphologically Similar Tumor Types. Cancer Res Commun. 2025 Nov 01; 5(11):1952-1966.
-
Selective Alanine Transporter Utilization Is a Therapeutic Vulnerability in ARID1A-Mutant Ovarian Cancer. Cancer Res. 2025 Sep 15; 85(18):3471-3489.
-
Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth. Mol Cancer Ther. 2025 Aug 01; 24(8):1252-1264.
-
NNMT inhibition in cancer-associated fibroblasts restores antitumour immunity. Nature. 2025 Sep; 645(8082):1051-1059.
-
Spatial proteo-transcriptomic profiling reveals the molecular landscape of borderline ovarian tumors and their invasive progression. Cancer Cell. 2025 Aug 11; 43(8):1495-1511.e7.
-
A Proteogenomic View of Synchronous Endometrioid Endometrial and Ovarian Cancer. Clin Cancer Res. 2025 Jun 03; 31(11):2230-2240.
-
Adaptive immune response and PD-1/ PD-L1 status in chemotherapy treated high grade serous carcinoma is dependent on chemotherapy response score. Hum Pathol. 2025 May; 159:105800.
-
Comparative Molecular Profiling of "Mixed Endometrioid Adenocarcinoma and Adenosarcoma" of the Uterus and Ovary: A Multi-institutional Series of 14 Cases. Am J Surg Pathol. 2025 Apr 07; 49(8):789-799.
-
Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor a-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial. Lancet Oncol. 2025 Apr; 26(4):503-515.
-
An open-label randomized active-controlled phase II clinical study to assess the efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer (PROFECTA-II/GOG-3044). Gynecol Oncol. 2025 Mar; 194:145-152.